Innovations in Heart Failure Pharmacotherapy

Heart failure (HF) remains a leading cause of morbidity and mortality, but recent innovations in pharmacotherapy are reshaping treatment paradigms. This session will highlight cutting-edge therapies for heart failure, focusing on new drug classes, including sodium-glucose co-transporter 2 (SGLT2) inhibitors, neprilysin inhibitors, and the expanding role of cardiac-specific gene therapies. Advances in personalized medicine, such as precision dosing based on genetic and biomarker profiles, will be discussed, along with novel combination therapies that address both symptoms and disease progression. The session will also explore the role of newer drugs in improving outcomes, reducing hospitalizations, and enhancing quality of life for heart failure patients

    Related Conference of Innovations in Heart Failure Pharmacotherapy

    January 29-30, 2026

    19th World Drug Delivery Summit

    Paris, France
    February 10-11, 2026

    40th World Congress on Pharmacology and Therapeutics

    Barcelona, Spain
    February 23-24, 2026

    3rd World Congress on Biologics and Biosimilars

    London, UK
    March 23-24, 2026

    36th Annual European Pharma Congress

    London, UK
    March 24-25, 2026

    11th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    April 16-17, 2026

    19th European Biosimilars Congress

    Rome, Italy
    April 27-28, 2026

    9th European Biopharma Congress

    Paris, Aland Islands
    May 28-29, 2026

    3rd International Conference on Pharmacognosy

    Madrid, Spain
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy
    September 24-25, 2026

    6th World Congress on Rare Diseases & Orphan Drugs

    Paris, France

    Innovations in Heart Failure Pharmacotherapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in